0001209191-12-003889.txt : 20120117
0001209191-12-003889.hdr.sgml : 20120116
20120117170647
ACCESSION NUMBER: 0001209191-12-003889
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120112
FILED AS OF DATE: 20120117
DATE AS OF CHANGE: 20120117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Williamson Robert F III
CENTRAL INDEX KEY: 0001397331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33428
FILM NUMBER: 12530205
MAIL ADDRESS:
STREET 1: 140 LASALLE AVENUE
CITY: PIEDMONT
STATE: CA
ZIP: 94610
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pharmasset Inc
CENTRAL INDEX KEY: 0001301081
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 303-A COLLEGE ROAD EAST
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 609-613-4100
MAIL ADDRESS:
STREET 1: 303-A COLLEGE ROAD EAST
CITY: PRINCETON
STATE: NJ
ZIP: 08540
4
1
c26691_4x0.xml
MAIN DOCUMENT DESCRIPTION
X0304
4
2012-01-12
1
0001301081
Pharmasset Inc
VRUS
0001397331
Williamson Robert F III
303-A COLLEGE ROAD EAST
PRINCETON
NJ
08540
1
0
0
0
Common Stock
2012-01-12
4
U
0
7000
137.00
D
0
D
Stock Option (Right to Buy)
1.94
2012-01-12
4
D
0
13333.33
0
D
2016-05-24
Common Stock
13333.33
0
D
Stock Option (Right to Buy)
1.94
2012-01-12
4
D
0
16000
0
D
2016-05-24
Common Stock
16000
0
D
Stock Option (Right to Buy)
2.01
2012-01-12
4
D
0
13333.33
0
D
2016-11-07
Common Stock
13333.33
0
D
Stock Option (Right to Buy)
6.84
2012-01-12
4
D
0
20000
0
D
2017-10-10
Common Stock
20000
0
D
Stock Option (Right to Buy)
10.10
2012-01-12
4
D
0
20000
0
D
2018-07-16
Common Stock
20000
0
D
Stock Option (Right to Buy)
9.30
2012-01-12
4
D
0
40000
0
D
2018-10-29
Common Stock
40000
0
D
Stock Option (Right to Buy)
10.83
2012-01-12
4
D
0
40000
0
D
2019-10-14
Common Stock
40000
0
D
Stock Option (Right to Buy)
16.17
2012-01-12
4
D
0
40000
0
D
2020-10-14
Common Stock
40000
0
D
Stock Option (Right to Buy)
83.52
2021-10-11
Common Stock
15000
0
D
Represents shares of time vesting restricted stock, reflecting the two-for-one stock split of the Issuer's common stock effective August 31, 2011 (the "Split"), which became unrestricted and eligible for tender pursuant to the Agreement and Plan of Merger between the Issuer and Gilead Sciences, Inc. (the "Merger Agreement").
These options, which reflect the Split and which vested as to 25% on the date of the grant (May 24, 2006), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $135.06 per share, representing the difference between the exercise price of the options and $137.00 per share.
These options, which reflect the Split and which vested on the date of grant (May 24, 2006), were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $135.06 per share, representing the difference between the exercise price of the options and $137.00 per share.
These options, which reflect the Split and which vested as to 25% on the date of grant (November 7, 2006), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $134.99 per share, representing the difference between the exercise price of the options and $137.00 per share.
These options, which reflect the Split and which vested as to 25% on the date of grant (October 10, 2007), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $130.16 per share, representing the difference between the exercise price of the options and $137.00 per share.
These options, which reflect the Split and which vested as to 25% on the date of grant (July 16, 2008), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.90 per share, representing the difference between the exercise price of the options and $137.00 per share.
These options, which reflect the Split and which vested as to 25% on the date of grant (October 29, 2008), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $127.70 per share, representing the difference between the exercise price of the options and $137.00 per share.
These options, which reflect the Split and which provided for vesting as to 25% on the date of grant (October 14, 2009), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.17 per share, representing the difference between the exercise price of the options and $137.00 per share.
These options, which reflect the Split and which provided for vesting as to 25% on the date of grant (October 14, 2010), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $120.83 per share, representing the difference between the exercise price of the options and $137.00 per share.
These options, which provided for vesting as to 25% on the date of grant (October 11, 2011), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $53.48 per share, representing the difference between the exercise price of the options and $137.00 per share.
/s/ Bryce A. Roberts, Attorney in Fact for Robert F. Williamson III
2012-01-17